Due to excutive director Annie Brandt's work with Best Answer for Cancer Foundation, the Recognize Good Foundation selected her for the 2012 March Legend Award. Since 2004, Annie has given her money, time and energy to the goals listed above. She spends countless hours every week on the phone with cancer patients, listening and sharing information. All her services are pro-bono.
IPT manipulates the mechanisms of malignancy to therapeutic advantage by employing insulin as a biologic response modifier of cancer cells' endogenous molecular biology. The autonomous proliferation of malignancy is supported by autocrine secretion of insulin for glucose/energy uptake by cancer cells, and a similar autocrine and/or paracrine elaboration of cellular factors to stimulate cancer growth. Amongst these, the insulin-like growth factors have been identified as the most potent mitogens for cancer cells. Of primary importance for IPTLD™, cancer cell membranes also have six times more insulin receptors and ten times more IGF receptors, per cell, than the membranes of host normal tissues. Further, insulin can cross-react with and activate cancer cell IGF receptors. Thus, per cell, cancer has sixteen times more insulin-sensitive receptors than normal tissues. As ligand effect is a function of receptor concentration, these facts serve to differentiate cancer from normal cells - a vital consideration for the safety of cancer chemotherapy.
See stories from IPT/IPTLD patients. Read about their triumphs and consider options for yourself.